A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics &Preliminary Anti-Cancer Efficacy of ABM-1310 in Patients With BRAF V600-Mutant Relapsed &Drug Resistant Primary Malignant Brain Tumors
Latest Information Update: 02 Dec 2024
At a glance
- Drugs ABM 1310 (Primary)
- Indications Astrocytoma; Brain cancer; Glioblastoma
- Focus Adverse reactions
- Sponsors ABM Therapeutics
Most Recent Events
- 28 Nov 2024 Status changed from recruiting to discontinued.
- 01 Sep 2023 According to an ABM Therapeutics media release, first patient has been dosed.
- 29 Jun 2023 Status changed from not yet recruiting to recruiting.